NovaBridge Biosciences's top three insider shareholders as of September 29, 2026 are Cong Claire Xu (Evp, Clinical Development, 304.20K shares), Sean Wuxiong Cao (Chief Bus. Development Officer, 266.47K shares), Mark Arnold Hagler (Officer, 230.00K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Cong Claire Xu | Evp, Clinical Development | 304,201 | 0 | 304,201 | 30.7% | 01 Sep, 2026 |
| 2 | Sean Wuxiong Cao | Chief Bus. Development Officer | 266,467 | 0 | 266,467 | 26.9% | 11 Sep, 2026 |
| 3 | Mark Arnold Hagler | Officer | 230,000 | 0 | 230,000 | 23.2% | 28 Apr, 2026 |
| 4 | Phillip Andrew Dennis | Chief Medical Officer | 173,427 | 0 | 173,427 | 17.5% | 21 Sep, 2026 |
| 5 | Robert A. Lenz | Director | 17,218 | 0 | 17,218 | 1.7% | 25 Aug, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 17 Sep, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Acquired M | 23,695 | — | — | 181,636 | Direct |
| 18 Sep, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Disposed S | 8,209 | $0.71 | $5.83K | 173,427 | Direct |
| 17 Sep, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Disposed M | 10,302 | $0.00 | $0 | 72,120 | Direct |
| 09 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Disposed S | 107,978 | $0.74 | $79.90K | 266,467 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Acquired M | 235,136 | — | — | 270,209 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Acquired M | 104,236 | — | — | 374,445 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Disposed M | 102,233 | $0.00 | $0 | 306,700 | Direct |
| 03 Sep, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Disposed M | 45,320 | $0.00 | $0 | 135,960 | Direct |
| 30 Aug, 2026 | Cong Claire Xu | Evp, Clinical Development | Acquired M | 9,382 | — | — | 307,483 | Direct |
| 31 Aug, 2026 | Cong Claire Xu | Evp, Clinical Development | Disposed S | 3,282 | $0.79 | $2.59K | 304,201 | Direct |
| 30 Aug, 2026 | Cong Claire Xu | Evp, Clinical Development | Disposed M | 4,079 | $0.00 | $0 | 28,558 | Direct |
| 22 Aug, 2026 | Robert A. Lenz | Director | Acquired M | 17,218 | — | — | 17,218 | Direct |
| 22 Aug, 2026 | Robert A. Lenz | Director | Disposed M | 7,486 | $0.00 | $0 | 14,974 | Direct |
| 08 Jul, 2026 | Liwei Lorraine Lin | General Counsel | Acquired A | 254,780 | $0.00 | $0 | 254,780 | Direct |
| 08 Jul, 2026 | Mark Arnold Hagler | Chief Commercial Officer | Acquired A | 949,050 | $0.00 | $0 | 949,050 | Direct |
| 06 Jul, 2026 | Srishti Gupta | Chief Executive Officer | Acquired A | 3,000,000 | $0.00 | $0 | 3,000,000 | Direct |
| 04 Jul, 2026 | Cong Claire Xu | Svp, Clinical Development | Acquired M | 12,432 | — | — | 302,586 | Direct |
| 06 Jul, 2026 | Cong Claire Xu | Svp, Clinical Development | Disposed S | 4,485 | $0.89 | $3.99K | 298,101 | Direct |
| 04 Jul, 2026 | Cong Claire Xu | Svp, Clinical Development | Disposed M | 5,405 | $0.00 | $0 | 0 | Direct |
| 29 Jun, 2026 | Wei Fu | Director | Acquired A | 725,140 | $0.00 | $0 | 725,140 | Direct |